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Abstract: The estrogenic effects of soy isoﬂ  avones (IF) on symptoms of menopause are 
of particular interest. The aim of the present study was to improve compliance of IF in 
two IF-enriched foods providing the same IF circulating levels in postmenopausal women. 
Forty-two healthy postmenopausal women (mean age: 53.28 years) were recruited for a 
randomized, crossover, multicenter trial conducted in the Netherlands, Italy and France. 
Over 18 days, volunteers were assigned to two groups and supplemented with two different 
IF-enriched foods (100 mg IF aglycones/two servings). The ﬁ  rst group had to eat two biscuits 
daily for three days. After a wash-out period (11 d), they received cereal bars for three days. 
The second group started with the cereal bars and ﬁ  nished with biscuits. After IF intake, plasma 
and urinary levels of genistein, daidzein, O desmethyl angolensin and equol signiﬁ  cantly 
increased and returned to baseline level after the washout period. There was no difference 
between biscuits and cereals bars intake, as shown by group values at each end of experimental 
period (day 4 or day 18). Both matrixes are comparable in terms of IF-circulating levels and 
could be used independently.
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Introduction
Current interest in soy foods is largely driven by documented research on the potential 
health beneﬁ  ts of phytoestrogens (Nomura et al 1978; Anderson et al 1995; Knight 
and Eden 1995). Soybeans are a staple of the Asian diet (Messina 1995). The main 
isoﬂ  avone exposure is 17.7 mg total isoﬂ  avones (IF) per day in China (Lui et al 2004) 
and 47.2 mg per day total IF in Japan (Arai et al 2000). In contrast, the estimated mean 
dietary daily IF intake reported for the UK was calculated to be 0.8 mg (Jones et al 
1989). The average consumption of phytoestrogens in Europe is estimated to be less 
than 2 mg/day (Boker et al 2002; Van Erp-Baart et al 2003). Consequently, an increase 
in soy consumption in Western countries could be a promising innovative target. 
A positive relationship has been demonstrated between the level of soy consumption 
and bone mineral density (Potter et al 1998). However, what is critical to biological 
efﬁ  cacy of these compounds is a thorough understanding of their bioavailability from 
different soya foods (Pascual-Teresa et al 2006). Indeed, the composition of the IF 
glucoside conjugates, which is altered during the industrial processing and cooking 
(Coward et al 1998), should modify the rate of absorption and possibly the degree of 
further metabolism.
Futhermore, the variability of IF bioavailability can also be due to inter-individual 
differences in IF metabolism (Rowland et al 2003). As a matter of fact, only 20%–35% 
of the adult population is able to convert daidzein into equol after ingesting soy or 
soy derivative products (Setchell et al 2005). This conversion is carried out by the 
intestinal bacteria (Setchell et al 1984; Atkinson et al 2005). These inter-individual 
differences could, at least, partially explain the differences in the biological effects Clinical Interventions in Aging 2008:3(4) 712
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observed following soy consumption. In a 2-year study 
carried out in post-menopausal women who drank 500 ml 
of soymilk either with or without IF, greater effects on bone 
health were elicited when volunteers were able to produce 
equol (Lydeking-Olsen et al 2002).
This study is the ﬁ  rst step of an interventional multicenter 
trial which aimed to study the potential preventive effect 
of soy IF on bone mass in postmenopausal women 
(PHYTOS shared-cost European RTD program: the 
prevention of osteoporosis by nutritional phytoestrogens, 
QLK1-CT2000-00431). The purpose of this work package 
was to set up a pilot trial to improve compliance of IF in two 
IF-enriched foods providing the same IF circulating levels 
in postmenopausal women.
Materials and methods
Study design
The study was a randomized, crossover, parallel multicenter 
trial conducted in the Netherlands (TNO Quality of Life, 
Zeist), Italy (INRAN, Rome), and France (INRA, Clermont-
Ferrand). The protocol of this study was approved by the 
ethical committee in each country (the independent Medical 
Ethics Committee of TNO for the Netherlands, The Medical 
Ethics Committee of the University of Rome “La Sapienza” 
for Italy and the “Comité Consultatif de Protection des 
Personnes dans la Recherche Biomédicale” for France).
Subjects were healthy Caucasian females selected via a 
phone questionnaire. All the volunteers gave their written 
informed consent. In each country, 14 healthy ambulatory 
postmenopausal women, less than ﬁ  ve years and menstrual 
bleeding within 12 months, (mean age: 53.28, range from 
49 to 60 years; mean age at menopause: 50.78 years) were 
recruited and completed the study. Subjects had a body mass 
index (BMI) ranging from 20 to 29 kg/m2. Subjects were 
randomly allocated to two group with BMI, age and time 
since last menses as randomization variables.
Subjects osteoporotic, with severe scoliosis, with a 
history of medical or surgical events that might signiﬁ  cantly 
affect the study outcome, or who were using a concomitant 
medication known to affect bone metabolism were excluded. 
Interfering habits such as strict vegetarian and vegan, high 
ﬁ  ber and high soy diets, allergy for soy, and frequent alco-
hol consumption ( 2 drinks/day,  15 drinks/week) were 
considered as exclusion criteria, as well. Participants were 
willing to take soy-enriched products, had not been involved 
in any clinical trial six months before entering this study 
and, were not in the exclusion period of the national index 
of healthy volunteers.
Volunteers underwent a screening visit that included a 
health history questionnaire, a physical examination and 
routine blood chemistry. The nutrition history questionnaire 
was used to investigate usual dietary intake patterns.
During the whole study (18 days), volunteers were 
requested to consume their habitual diet, although they 
were given detailed dietary instructions to minimize pre-
biotics-containing food products or to avoid phytoestrogen 
consumption. Subjects were assigned to one of two groups 
(seven women each). Two different IF-enriched foods were 
provided to the volunteers: biscuits (Danone Vitapole, Palais-
eau France) and cereals bars (Nutrition Santé, Revel, France). 
They both were designed to bring 100 mg IF aglycones in two 
servings (60%–75% genistein; 23%–35% daidzein; 1%–5% 
glycitin; 83.5 mg IF glycosyled; Prevastein®HC, Eridania 
Beghin-Say, Vilvoorde, Belgium). The composition is given 
in Table 1. The ﬁ  rst group of volunteers had to eat, including 
meals, two IF-enriched biscuits daily for three days (D1–D3). 
After a wash-out period of 11 days (D4–D14), under the same 
conditions they were provided two IF-enriched cereal bars 
for three days (D15–D18). The second group started with 
the cereal bars and received the biscuits during the second 
period (Figure 1).
Compliance with consumption was monitored by a 
combination of specially designed forms and return of 
unconsumed foods throughout the study and the assessment 
of plasma and urinary IF concentrations at four time 
points.
Sample size calculation
The sample size has been calculated to detect differences in 
plasma levels of total IF between groups consuming different 
food matrixes equal to ½ SD (0.15 μmol/L) observed in 
12 adult women after a single dose of 126 mg IF administered 
as soy milk (Xu et al 1994). A total of 42 subjects (14 per 
country) is required to detect differences between groups 
with 80% power, signiﬁ  cance level set at 0.05, and assuming 
a 20% drop-out rate.
Blood and urine collection
At days 1, 4, 15, and 18, 7 ml of blood were collected by venous 
puncture, ie, a total volume of 28 ml. The volunteers were 
asked to fast since their dinner on the previous day. Venous 
blood samples were drawn on heparin tubes subjected to 
centrifugation (2000 g × 10 min at 4 °C). Then plasma was 
aliquoted and frozen (−80 °C) for genistein and daidzein 
analysis and one was archived.Clinical Interventions in Aging 2008:3(4) 713
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Subjects were also required to complete a 24-h urine 
samples collection before each visit (from 7am the previous 
day to 7am the visit day) on days 1, 4, 15, and 18 and brought 
back the ﬂ  ask. The volume of each 24-h urine sample was 
measured, and subsamples were taken, adding 0.1% ascorbic 
acid and frozen (−20 °C) until genistein, daidzein, equol and 
O-DMA analysis. One aliquot was archived.
Isoﬂ  avone assessment
Genistein and daidzein were analyzed, in duplicate in plasma, 
by RIA (TR-FIA), using as internal standard tritiated estradiol 
beta-glucuronide. The sensitivity limit of the method is 
1.8 pg/μl, 0.35 nM, being recovery calculated after hydrolysis 
and extraction.
Genistein, daizein, equol and O-DMA were analyzed 
in duplicate in urine sample by GC/SIM, using deuterium 
labeled internal standards. In this method, isoﬂ  avonoids 
were hydrolyzed and measured as free aglycones. This 
newly-developed immunoassay for IF was compared with 
GC/MS and HPLC methods to ensure adequate performance 
in terms of their precision, speciﬁ  city and spiking/recovery 
of added synthetic isoﬂ  avones (Adlercreutz et al 2004).
Statistics
The data are expressed as individual values and means ± 
standard error of the mean (SEM). Statistical tests have been 
chosen according to the data distribution (Kolmorogov–
Smirnov test). For each group a comparison was established 
between results at the ﬁ  rst experimental day and after three 
days of consumption. Analysis of variance (ANOVA) was 
used to test for any signiﬁ  cant difference among groups. 
These tests were carried out under Statview software 
(Microsoft, San Diego, CA, USA). A two-way ANOVA was 
performed, one way for the country and the other way for 
the treatment. When ANOVA was signiﬁ  cant the Student’s 
T-test was used.
Table 1 Composition of the investigational products per 100 g 
of product1
Nutritional analysis Biscuits Bars
Energy (Kj) 1846 1600
Moisture (g) 2.6 8.6
Protein (g) 6.6 6.0
Carbohydrates (g) 64.3 77.9
 Sugars  (g) 26.3 24.1
Fat (g) 17.3 4.4
  Saturated fatty acids (g) 4.3 2.2
  Monounsaturated fatty acids (g) 8.9 0.2
  Polyunsaturated fatty acids (g) 4.0 1.5
Fibers (g) 6.6 1.7
Isoﬂ  avones aglycones (mg) 444 254
Minerals
 Calcium  (mg) 21 15
 Magnesium  (mg) 36 40
 Phosphorus  (mg) 131 103
 Iron  (mg) 1.22 1.03
Note: 1The subjects received combinations of the products equalling 24 g/d biscuits 
or 12 g/d bars.
D1 D0 D2 D4 D6 D8 D10  D-15  D3 D5 D7 D9 D11 D12   D13   D14  D15   D16  D17 D18
Informed consent 
Medical history 
Dietary record 
Physical exam
Group 1 
Group 2 
IF consumption
Period 1 
IF consumption
Period 2
Consumption of IF-enriched food 1 (biscuits, 50 mg aglycones isoflavones per portion, 2 servings a 
day out of the meals) 
Consumption of IF-enriched food 2 (cereal bars, 50 mg aglycones isoflavones per portion, 2 servings 
a day out of the meals) 
Blood sampling for genistein and daidzein measurement 
24h urines collection for the detection of genistein, daidzein, equol and O-DMA  
Figure 1 Study design to test the effect of food matrix on isoﬂ  avones bioavailability in early postmenopausal women. Clinical Interventions in Aging 2008:3(4) 714
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Results
Effect of food matrix on isoﬂ  avones 
bioavailability
In France, urinary and plasma levels of genistein and daidzein 
followed the same pattern, ie, an increase at day 4 and 18 
(Figure 2). Basal plasma genistein levels at day 1 were not 
signiﬁ  cantly different from those measured at the beginning 
of the second experimental period (day 15). Daidzein 
concentrations followed the same pattern. Consequently, the 
wash-out period was efﬁ  cient. Whatever the IF consumption 
period, plasma concentrations increased after 3 days and 
values reached similar levels at day 4 and day 18.
Urinary levels of genistein and daidzein followed the 
same pattern than in plasma, ie, an increase at day 4 and 18, 
concentrations at the beginning of each experimental period 
being similar. Equol or O-DMA excretion exhibited same 
behavior than genistein or daidzein.
The two food matrix did not have any inﬂ  uence on equol 
productions, as shown by the number of equol producers and 
non producers (Figure 3).
Isoﬂ  avones bioavailability in each country
Whatever the period, plasma genistein levels did not differ 
among volunteers in each center. The highest basal levels of 
Figure 2 Effect of isoﬂ  avones-enriched biscuits (   ) or isoﬂ  avones-enriched cereal bars ( ) consumption for 3 days (day 1 to day 4 and day 15 to day 18) on plasma genistein 
and daidzein levels, and urinary genistein, daidzein, equol and O-DMA concentrations. Values are expressed as means ± their standard errors (values for each country have 
been plotted together). Means values were all signiﬁ  cantly different from day 1 or day 15. 
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daidzein were measured in Netherlands and being even lower 
in France than in Italy. After three days of IF consumption, 
daidzein values were similar in all three countries except at 
day 4 in Italy.
In Netherlands, genistein urinary excretion was lower 
(p   0.05) than in France and in Italy at day 4 and 18. 
Daidzein urinary excretion was lower (p   0.05) than those 
in Italy (Figure 4).
Average equol excretion rate (nmol/24 h) was much 
lower in the Netherlands than in the other countries 
(France: 5212 ± 1268; Italy: 3218 ± 1268). In the 
Netherlands, only 28.6% of the volunteers were considered 
as high equol producers ( 1000 nmol/24 h), against 57% 
in France and the average urinary production among those 
producers (nmol/24 h) was much lower than in the other 
countries (Table 2).
Discussion
Following soy food consumption, IF are biotransformed 
by intestinal microﬂ  ora, a required step for absorption. 
IF are hydrolyzed by glucosidases to the aglycones daidzein, 
genistein and glycitein. Some are further metabolized to 
compounds such as equol, dihydrodaidzein and p-ethylphenol. 
Equol is more estrogenic than its precursors, whereas, 
p-ethylphenol is nonestrogenic. Daidzein is formed from 
formononetin and is metabolized into equol and O-DMA. 
Genistein is formed from biochanin A and metabolised 
to p-ethylphenol. Elimination of IF is predominantly via 
the urine (mainly equol), although total recovery by mass 
balance is less than 50%, suggesting that unrecognized 
metabolites are being formed. Only some pharmacokinetic 
studies have been conducted in which isoﬂ  avones were 
measured in human subjects simultaneously in plasma urine 
and feces (Xu et al 1994). Hutchins and colleagues (1995) 
determined the metabolites O-DMA and equol, in addition 
to genistein and daidzein in urine after intake of fermented 
and unfermented soy foods, but no analysis was performed 
in blood.
In the present study, IF plasma levels would reach a 
plateau after three days of IF-enriched food consumption 
and would return to baseline after a wash-out period 
of one week. A signiﬁ  cant increase in both plasma and 
urinary IF was shown after three days of consumption and 
concentrations returned to basal level in 15 days (wash-out 
period). This pattern was demonstrated to be similar in each 
of the three countries. According to data at the time the 
experiment started, elimination half-lifes of genistein and 
daidzein were considered to be short: 8 to 10 h and 6 to 8 h 
for genistein and daidzein, respectively. Moreover, several 
studies demonstrated entero-hepatic recirculation phenomena 
Figure 3 Effect isoﬂ  avones-enriched biscuits (b) or isoﬂ  avones-enriched cereal bars (c) consumption for 3 days (day 15 to day 18) on urinary equol excreation at day 18. 
Individual values are given in each country (the Netherlands (   ), France (   ) and italy (   ), values above the dotted line (at 1000 nmol/24 h) were harvested in volunteers 
considered as high producers.
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which lead to rather higher parameters up to 20 h for both 
IF (Richelle et al 2002; Vergne et al 2007).
In the present study plasma level reached quite high levels 
after consumption of IF-enriched biscuits or IF-enriched bars 
(nmol/l magnitude). In addition, because Prevastein contains 
more genistein (167 mg IF glycosyled/day composed of 
100–125 mg genistein, 42–58 mg daidzein and 1.67–8.35 
mg glycitin), the higher genistein concentrations than daizein 
make sense. In each country, daidzein concentrations in 
plasma were lower than those of genistein which reﬂ  ect 
the ingested proportions and the reverse was observed in 
the urine samples. This is in accordance with previous 
studies undertaken on humans and rats (Setchell et al 2003; 
Mathey et al 2006) showing that daidzein excretion is higher 
than that of genistein. This phenomenon reﬂ  ects a greater 
bioavailability of daidzein.
Several investigators have reported that individual 
variability in colonic microﬂ  ora plays an important role 
in determining the preferred pathways of isoﬂ  avones 
metabolism and the bioavailability of isoﬂ  avones. There 
is variation in the ability of the bacteria to produce equol, 
about 30%–50% of the adult population does not excrete 
Figure 4 Effect of isoﬂ  avones-enriched food consumption for three days (day 1 to day 4 and day 15 to day 18) on plasma genistein and daidzein levels, and urinary genistein, 
daidzein, equol and O-DMA concentrations in the Netherlands ( ), France (   ) and Italy (    ). 
Notes: Values are expressed as means ± their standard errors. Values for both biscuits and cereal bars have been plotted together. Means values were all signiﬁ  cantly different 
from day 1 or day 15. ap   0.05 vs concentrations in France; *p   0.05 vs concentrations in The Netherlands, +p   0.05 vs concentrations in Italy.
n
m
o
l
/
2
4
 
h
Urinary O-DMA
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
♦
Urinary daidzein
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
n
m
o
l
/
2
4
 
h
Urinary equol
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
n
m
o
l
/
2
4
 
h
*
Urinary genistein
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
n
m
o
l
/
2
4
 
h
♦
n
m
o
l
/
l
Plasma genistein 
0
500
1000
1500
2000
2500
Day 1
Plasma daidzein
0
500
1000
1500
2000
2500
n
m
o
l
/
l
*
♦
+
+ +
+
+
♦
+
♦
+
♦
*
*
*
+
*
*
+ +
*
*
*
+ +
*
*
♦ ♦
France Italy The Netherlands
Day Day Day 18 Day Day Day 15 Day
Day 1 Day 4 Day 15 Day 18 Day 1 Day 4 Day 15 Day 18
Day 1 Day 4 Day 15 Day 18 Day 1 Day 4 Day 15 Day 18Clinical Interventions in Aging 2008:3(4) 717
Soy isoﬂ  avones bioavailability in postmenopausal women
Table 2 Ability to produce equol in The Netherlands, France and Italy
The Netherlands France Italy
Non equol producers ( 500 nmol/24 h) 64.3% 28.6% 53.8%
Low equol producers ( 500 nmol/24 h) 7% 14% 15.4%
High equol producers ( 1000 nmol/24 h) 28.6% 57% 30.8%
Average production in high producers (nmol/24 h) 2401 ± 841a 8906 ± 1765 7671 ± 1933
Note: ap   0.05 vs values in France or Italy.
this bacterial metabolite in urine, when challenged daily 
with soy foods (Lampe et al 1998; Rowland et al 1999). 
In the early studies, it was found that two third of adults 
who consumed soy containing foods converted daidzein 
to equol (Setchell et al 1984). This ability to converted 
daidzein into equol led to use of the term “converters” 
to describe persons who have the necessary bacterial 
enzymes or intestinal conditions to make this biotrans-
formation (Setchell et al 2001). In the present study, we 
have shown a signiﬁ  cant difference in the ratio for equol 
producers in the three countries. IF was classiﬁ  ed in three 
groups; according to the magnitude of production: high, 
medium and very low, French volunteers had the most 
important percentage of high equol producers (42%), in 
opposite to Italy (30%) or the Netherlands (21%). The very 
low producers were much numerous in The Netherlands 
and as volunteers exhibited quite important individual 
variations in basal plasma IF (including genistein and 
daidzein). Consequently, it can be hypothesized that 
country differences may be explained by dietary factors. 
This trend will have to be checked in the main trial on 
more postmenopausal women.
In this project, a difference in composition of product, in 
particular in ﬁ  ber level (6.6 g/100 g of biscuits vs 3.4 g/100 g 
of bars) would have been modiﬁ  ed the bioavailability of 
IF. Indeed, it has been established that concurrent dietary 
intake, in particularly ﬁ  bers, may exert a major inﬂ  uence on 
isoﬂ  avones metabolism, by modulating intestinal microﬂ  ora 
(Xu et al 1995). However, the level of IF did not appear to 
be altered by food matrix.
In conclusion, because the food matrix of biscuit or cereal 
bar does not modify IF metabolism, volunteers in the main 
intervention trial will have a choice between the biscuit or 
cereal bar.
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